ReviewCardiovascular diabetology2017
Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes.
Review in Cardiovascular diabetology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Correlation Between Epicardial Adipose Tissue and PET Cardiac Perfusion: A Systematic Review.Medical sciences (Basel, Switzerland) · 2026Pooled it
- Elevated Epicardial Adipose Tissue and Ischemic Stroke Risk: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Pathophysiology of Type 2 Diabetes in Children and Adolescents.Current diabetes reviews · 2020Pooled it
- Epicardial fat tissue in patients with diabetes mellitus: a systematic review and meta-analysis.Cardiovascular diabetology · 2019Pooled it
- Targeting body composition in an older population: do changes in movement behaviours matter? Longitudinal analyses in the PREDIMED-Plus trial.BMC medicine · 2021Trial
- Triglyceride-glucose index is associated with symptomatic coronary artery disease in patients in secondary care.Cardiovascular diabetology · 2019Trial
- Epicardial Adipose Tissue in Diabetic Heart Disease: Impact on Cardiac Function and Modulation Strategies, a Comprehensive Review.Medicina (Kaunas, Lithuania) · 2026Review
- Association of the ITLN1 gene polymorphism with dietary patterns, glycemic factors, and anthropometric indices in women with prediabetes.Genes & nutrition · 2026Article
- Low BMI predicts mortality in T2DM older adults: cholesterol parameters demonstrate negative mediation.Diabetology & metabolic syndrome · 2026Article
- Association of plasma C1q/TNF-related protein 9 levels with disease severity and prognosis in patients with coronary atherosclerotic heart disease.Scientific reports · 2026Article
- Increasing the rigor of body composition and adiposity measurement in multiple sclerosis research.Frontiers in neurology · 2026Review
- Obesity-Associated Cardiac Fibrosis: Mechanisms and Emerging Therapeutic Targets.Vascular health and risk management · 2026Review
- Article
- Epicardial Adipose Tissue-A Novel Therapeutic Target in Obesity Cardiomyopathy.International journal of molecular sciences · 2025Review
- Single-Cell and Single-Nuclei transcriptomics profiling reveals dynamic cellular features in tumor-related adipose microenvironment of breast cancer patients with high BMI.Translational oncology · 2025Article
- Epicardial adipose tissue: a new link between type 2 diabetes and heart failure-a comprehensive review.Heart failure reviews · 2025Review
- Anthropometric and metabolic parameters associated with visceral fat in non-obese type 2 diabetes individuals.Diabetology & metabolic syndrome · 2025Article
- Relationship Between Monocyte-to-High-Density Lipoprotein Cholesterol Ratio and Visceral Obesity in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Remodeling of the Intracardiac Ganglia During the Development of Cardiovascular Autonomic Dysfunction in Type 2 Diabetes: Molecular Mechanisms and Therapeutics.International journal of molecular sciences · 2024Review
- Article
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nowadays, obesity is seriously increasing in most of the populations all over the world, and is associated with the development and progression of high-mortality diseases such as type-2 diabetes mellitus (T2DM) and its subsequent cardiovascular pathologies. Recent data suggest that both body fat distribution and adipocyte phenotype, can be more determinant for fatal outcomes in obese patients than increased general adiposity. In particular, visceral adiposity is significantly linked to long term alterations on different cardiac structures, and in developed forms of myocardial diseases such as hypertensive and ischaemic heart diseases, and diabetic cardiomyopathy. Interestingly, this depot may be also related to epicardial fat accumulation through secretion of lipids, adipokines, and pro-inflammatory and oxidative factors from adipocytes. Thus, visceral adiposity and its white single-lipid-like adipocytes, are risk factors for different forms of heart disease and heart failure, mainly in higher degree obese subjects. However, under specific stimuli, some of these adipocytes can transdifferentiate to brown multi-mitochondrial-like adipocytes with anti-inflammatory and anti-apoptotic proprieties. Accordingly, in order to improve potential cardiovascular abnormalities in obese and T2DM patients, several therapeutic strategies have been addressed to modulate the visceral and epicardial fat volume and phenotypes. In addition to lifestyle modifications, specific genetic manipulations in adipose tissue and administration of PPARγ agonists or statins, have improved fat volume and phenotype, and cardiovascular failures. Furthermore, incretin stimulation reduced visceral and epicardial fat thickness whereas increased formation of brown adipocytes, alleviating insulin resistance and associated cardiovascular pathologies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.